BioSpace News Archive

The three-year agreement leverages AvantGen’s yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.

Terray Therapeutics has generated $60 million from a Series A financing round just shortly after getting $20 million in seed funding for the AI drug discovery.

After announcing that the FDA was investigating a possible death associated with its lymphoma drug Ukoniq (umbralisib), things are seemingly looking up for TG Therapeutics.

Shares of ImmunoGen are climbing this morning after the company announced an antibody drug conjugate (ADCs) collaboration with Eli Lilly valued at up to $1.7 billion.

Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the launch of Spanish-language availability for reSET® and reSET-O®, the only FDA-authorized PDTs for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively.

PAVmed Inc., a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc., announced the appointment of prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors.

NanoMosaic Inc., the pioneer and leader in nanoneedle (MosaicNeedle™) technology detection for proteomics, genomics, and single-run experiment multi-omics applications, has announced its second commercial sale, to Massachusetts General Hospital (MGH) as part of its Early Access Program.

Bay Area biotech firm renegade.bio today announced its partnership with Metabolomic Diagnostics, the Irish deep tech company specializing in the development of novel disease diagnostic solutions.

Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference.